GLP-1 Drugs Show Benefits Far Beyond Weight Loss

Research presented this week suggests GLP-1 medications may cut asthma attacks, cancer risk and more, though experts urge evidence before wider use.

today.com reports that research keeps uncovering potential benefits of GLP-1 drugs beyond weight loss and diabetes, with the most recent discovery suggesting a GLP-1 medication can reduce asthma attacks. Findings presented at the European Respiratory Society Congress on Sept. 8 linked semaglutide to nearly a 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups, though lead author Chloe Bloom cautioned the record-based findings need confirmation in clinical trials. Yale cardiologist Dr. Harlan Krumholz, who spoke to today.com, calls the class 'generational breakthrough medications' and says each trial feels like 'this winning streak that just continues.'

The breadth of effects is what sets GLP-1s apart from typical weight-loss drugs. today.com explains that GLP-1 receptors are found throughout the body — with the brain holding the highest density, but receptors also present in the pancreas, GI tract, heart, vasculature, kidneys, lungs and thyroid. Dr. Natalie Azar, an NBC News medical contributor and rheumatologist, told TODAY she finally saw reductions in systemic inflammation only after some patients started these medicines, leading her to expect applications 'far beyond' weight loss and diabetes. Krumholz emphasizes that weight loss alone does not fully explain what is going on.

Several benefits are already FDA-approved, according to today.com: Mounjaro was approved on Aug. 28 to lower major cardiovascular risk in adults with Type 2 diabetes; Zepbound is the first approved medication for obstructive sleep apnea; Ozempic is approved to reduce kidney disease worsening in adults with Type 2 diabetes and chronic kidney disease; and Wegovy is approved to treat severe fatty liver disease (MASH). today.com also cites a 2026 study associating GLP-1 use with a 41% lower risk of obesity-related cancers, and research on reduced alcohol and substance-use disorder risks. Krumholz co-authored a paper finding tirzepatide lowered systolic blood pressure by almost seven points versus placebo.

Experts urge restraint before prescribing GLP-1s preventively to healthy people. today.com reports Dr. Nicolas Musi of Cedars-Sinai calls it 'very premature' to assume benefits in people without disease, pointing to low-dose aspirin as a cautionary tale where guidance changed once evidence showed it wasn't beneficial for most healthy adults. The lesson echoes across medicine: even highly effective drugs leave gaps. A study covered by Cystic Fibrosis News Today found children and adolescents with cystic fibrosis still face elevated anxiety, depression and sleep problems despite Trikafta, with caregiver mental health tied to their children's symptoms — a reminder that blockbuster therapies rarely solve everything.

Krumholz told today.com he wonders whether researchers should test GLP-1 microdosing — much lower doses than currently recommended — to boost cardiometabolic health, possibly even in people without obesity, and whether at-risk women might one day be tested for breast-cancer prevention. Musi's team is studying whether GLP-1s can slow biological aging, and Novo Nordisk told today.com it continues investing in research across a diverse set of complications. Commercial momentum extends beyond human medicine: according to Stock Titan, Cosmos Health launched its C-ScrubVet veterinary cleanser in the UK on Sept. 9, entering an estimated $69 billion global animal health market.